Piper Sandler cuts Braze but doubles its target, as options hit a 52-week low PCR

Piper Sandler downgraded BRZE to Neutral on Tuesday, yet raised its price target to $47.50 from $30, implying 58% upside from Monday's close of $30.04. The rating cut after a 23% one-month rally is the kind of move that says "great run, now be careful." The options market is not listening.

Options market at its most bullish in a year

The put-call ratio hit 0.141 on October 19, just above the 52-week low of 0.1409. That is 3.1 standard deviations below the 20-day mean of 0.233. Call buying has overwhelmed put buying to a degree not seen in the past year. The PCR has declined almost every session since mid-September, when it stood above 0.38.

That shift is not subtle. Six weeks ago, for every put purchased there were roughly 2.6 calls. Now there are more than seven calls for every put. Piper Sandler's downgrade landed into one of the most aggressively bullish options setups BRZE has seen in recent memory.

Retail attention joins the crowd

Wikipedia views and ORTEX stock page traffic for Braze are running 4.8 standard deviations above their 90-day average as of October 19. Retail attention at that level tends to follow a sharp price move rather than precede one, but it does tell you the stock has crossed from specialist to general awareness. The 23% monthly gain has put Brze on screens it was not on before.

Where the analyst community stands

The consensus remains "buy," with 11 buy ratings, 5 outperforms and 3 holds. The mean price target is $38.69, well below Piper Sandler's new $47.50. Citizens (Market Outperform, $35) and BTIG (Buy, $35) both reiterated in early October without moving their targets. DA Davidson holds a Buy at $40. JP Morgan cut its target to $34 from $35 in September but kept Overweight.

FMR LLC is the largest institutional holder at 15% of shares, and raised its stake materially in its last disclosure (as of August 6). BlackRock also added shares in its most recent filing. Short interest sits at 8% of free float, down 17% over the past month as the stock rallied.

What to watch

Next earnings are scheduled for December 10. That gives seven weeks for the Piper Sandler thesis, quality business, extended valuation, hold the position, to be tested against a stock market that is currently pricing in something more optimistic. The PCR and whether it can hold below 0.20 is the clearest near-term gauge of whether options conviction behind the rally is building or fading.